SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (229)11/8/2001 7:36:47 AM
From: Jim Oravetz  Read Replies (1) of 278
 
UCSD Researchers Suggest Naturally Occurring Molecules May Alleviate Build-Up Of Plaque In Parkinson's Patients
Source: University Of California - San Diego (http://www.ucsd.edu/)
Date: Posted 11/8/2001

Naturally occurring molecules called beta-synucleins (b-synucleins) may have the ability to halt the excessive build-up of plaque-like deposits, called Lewy bodies, that are found in the dying neuron cells of Parkinson’s disease patients, according to researchers in the University of California, San Diego (UCSD) School of Medicine.
In findings published recently in the journal Neuron, investigators in the lab of senior author Eliezer Masliah, M.D., professor of neurosciences and pathology, showed in mice that b-synuclein inhibits the Lewy body-producing activity of a cousin molecule called alpha-synuclein, which has been linked to abnormal accumulation of Lewy bodies characteristically seen in the brain’s of Parkinson’s patients.

Although the mechanism by which b-synuclein works to block a-synuclein Lewy body-formation is unknown, Masliah and his colleagues noted that an imbalance in the ratio of a- to b-synuclein might render a-synuclein more prone to the plaque-like development.

In test tube studies, the research team added b-synuclein to a-synuclein protein that had formed aggregates, the abnormal Lewy body deposits. When b-synuclein was added, the aggregates untangled.

In studies with mice, the researchers first developed one group with over-expressed a-synuclein and another group with large amounts of b-synuclein. The a-synuclein mice developed Lewy bodies while the b-synuclein group did not.

When the researchers developed mice bred with higher amounts of b-synuclein, compared to a-synuclein (such as in normal individuals), the b-synuclein ameliorated the motor deficits, neurodegenerative alteration, and neuronal a-synuclein accumulation of Lewy bodies that had been seen in the a-synuclein mice.

In addition to Masliah, the research team included first author Makoto Hashimoto, M.D.; Edward Rockenstein, B.S.; Michael Mante, B.S.; and Margaret Mallory, B.S., all in the UCSD Departments of Neurosciences and Pathology.

The research was supported by grants from the National Institute of Health and the Michael J. Fox Foundation for Parkinson’s Research.



--------------------------------------------------------------------------------

Note: This story has been adapted from a news release issued by University Of California - San Diego for journalists and other members of the public. If you wish to quote from any part of this story, please credit University Of California - San Diego as the original source. You may also wish to include the following link in any citation:

sciencedaily.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext